obinutuzumab

anti-CD20 mAb for treating B-cell lymphoid cancers

Also Known As:

GA 101; GA-101; GA101 antibody; Gazyva; R 7159; R-7159; R7159 cpd; RO 5072759; RO-5072759; RO5072759; afutuzumab; gazyvaro; Immunoglobulin G1, anti-(human CD20 (antigen)) (human-mouse monoclonal GA101 heavy chain), disulfide with human-mouse monoclonal GA101 KAPPA-chain, dimer

Networked: 465 relevant articles (82 outcomes, 144 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Klein, Christian: 25 articles (01/2022 - 07/2012)
2.	Cartron, Guillaume: 24 articles (01/2022 - 05/2012)
3.	Hallek, Michael: 19 articles (06/2022 - 03/2014)
4.	Stilgenbauer, Stephan: 18 articles (06/2022 - 03/2014)
5.	Morschhauser, Franck: 17 articles (01/2022 - 05/2012)
6.	Fischer, Kirsten: 16 articles (06/2022 - 03/2014)
7.	Salles, Gilles: 16 articles (01/2022 - 05/2012)
8.	Nielsen, Tina: 14 articles (01/2022 - 11/2017)
9.	Hiddemann, Wolfgang: 13 articles (12/2022 - 02/2015)
10.	Sehn, Laurie H: 13 articles (10/2021 - 05/2012)

Related Diseases

1.	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 12/01/2017 - "Obinutuzumab Effective in Follicular Lymphoma, but at a Cost." 10/01/2020 - "Our study shows that the benefits of the use of obinutuzumab in the first-line treatment of follicular lymphoma extend beyond clinical advantages." 10/01/2020 - "In this study, we assessed the productivity gains associated with the use of obinutuzumab in combination with chemoimmunotherapy (G-chemo) in first-line treatment among follicular lymphoma patients. " 10/01/2020 - "The societal impact of obinutuzumab in the first-line treatment of patients with follicular lymphoma in Germany." 10/05/2017 - "Obinutuzumab for the First-Line Treatment of Follicular Lymphoma."
2.	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 11/13/2015 - "Obinutuzumab (GA101) is highly effective against chronic lymphocytic leukemia cells in ex vivo B-cell depletion irrespective of high-risk prognostic markers." 10/02/2014 - "GAUGUIN evaluated the safety and efficacy of obinutuzumab (GA101) monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). " 01/07/2016 - "Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia." 07/01/2015 - "Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study." 10/02/2014 - "Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study."
3.	Neoplasms (Cancer) 01/01/2016 - "Haematological cancer: Obinutuzumab effective against treatment-refractory NHL." 10/01/2014 - "This emerging data provide reasons to be optimistic that outcomes for patients with B-cell malignancies can be further improved with obinutuzumab." 01/01/2017 - "Obinutuzumab is under investigation in a wide-ranging program of clinical trials in patients with B-cell malignancies. " 05/31/2012 - "A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies." 06/01/2009 - "At the time of publication, phase I/II trials for GA-101 were ongoing in B-cell malignancies. "
4.	Non-Hodgkin Lymphoma (Lymphosarcoma) 06/01/2022 - "We established cells resistant to obinutuzumab-induced ADCC using the non-Hodgkin lymphoma cell line RL and examined their mechanisms of resistance and the combination efficacy of obinutuzumab and clinically available agents. " 08/01/2018 - "Safety, tolerability and pharmacokinetics of shorter duration of infusion of obinutuzumab in Japanese patients with B-cell non-Hodgkin lymphoma: final results of the phase II GATS study." 08/10/2013 - "Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study." 01/01/2013 - "Phase I study of obinutuzumab (GA101) in Japanese patients with relapsed or refractory B-cell non-Hodgkin lymphoma." 01/01/2021 - "Human non-Hodgkin lymphoma SU-DHL-4 cells were sustainably exposed to obinutuzumab in vitro, and 17 resistant clones expressing CD20 and showing 100-fold higher IC50 of obinutuzumab than parental cells were established. "
5.	Lymphoma (Lymphomas) 10/01/2017 - "A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells." 01/01/2017 - "A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells." 01/01/2022 - "We developed a predictive model (Tolerability of R-CHOP in Aggressive Lymphoma [TRAIL]) on the basis of a training data set from the phase III GOYA trial (obinutuzumab with CHOP v R-CHOP in 1L DLBCL) using a composite binary end point, identifying patients who prematurely stopped or required reductions of R-CHOP. " 01/01/2021 - "Noninvasive Evaluation of CD20 Expression Using 64Cu-Labeled F(ab')2 Fragments of Obinutuzumab in Lymphoma." 11/01/2019 - "Obinutuzumab outperformed the other mAbs with regard to direct target cell lysis and ADCC by γδ T cells in several CD20 cell lines and primary lymphoma specimens. "

Related Drugs and Biologics

1.	Rituximab (Mabthera)
2.	Chlorambucil (Leukeran)
3.	ibrutinib
4.	Bendamustine Hydrochloride
5.	Monoclonal Antibodies
6.	venetoclax
7.	Gallium
8.	acalabrutinib
9.	Antibodies
10.	Cyclophosphamide (Cytoxan)

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Retreatment
4.	Immunotherapy
5.	Aftercare (After-Treatment)